Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/20/24 | 8-K | Current report filing |
|
   |
4 |
| 05/16/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 05/16/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
14 | |
| 05/15/24 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 05/15/24 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
21 | |
| 05/14/24 | 8-K | Current report filing |
|
|
18 |
| 05/14/24 | 8-K | Current report filing |
|
|
5 |
| 05/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
23 |
| 05/09/24 | UPLOAD | SEC-generated letter |
|
1 | |
| 05/03/24 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
23 |
